Mechanisms of IL-33 processing and secretion: Differences and similarities between IL-1 family members

European Cytokine Network

Volumn 23, Issue 4, 2012, Pages 120-127

  Lefrançais, Emma ^a,b   Cayrol, Corinne ^a,b  

^a INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Caspase 1; IL 1 family; IL 33; Inflammatory proteases; Neutrophil serine proteases

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 33; INTERLEUKIN 5; PROTEINASE;

ASTHMA; CELL DAMAGE; ENZYME RELEASE; HUMAN; IMMUNE RESPONSE; NECROSIS; NONHUMAN; PARASITOSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; REVIEW;

CASPASE-1; IL-1 FAMILY; IL-33; INFLAMMATORY PROTEASES; NEUTROPHIL SERINE PROTEASES;

ANIMALS; HUMANS; INTERLEUKIN-1; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84873716709     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0320     Document Type: Review

References (75)

1. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nature Rev Immunol 2010; 10: 89-102.
2. Lingel A, Weiss TM, Niebuhr M, et al. Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors-insight into heterotrimeric IL-1 signaling complexes. Structure 2009; 17: 1398-410.
3. Thomas C, Bazan JF, Garcia KC. Structure of the activating IL-1 receptor signaling complex. Nature Struct Mol Biol 2012; 19: 455-7.
4. Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003; 163: 69-79.
5. Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-90.
6. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Ac Sci USA 2007; 104: 282-7.
7. Roussel L, Erard M, Cayrol C, et al. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9: 1006-12.
8. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Ac Sci USA 2009; 106: 9021-6.
9. Chen CJ, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-6.
10. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-37.
11. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10: 103-10.
12. Mirchandani AS, Salmond RJ, LiewFY. Interleukin-33 and the function of innate lymphoid cells. Trends Immunol 2012; 33: 389-96.
13. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Ann Rev Immunol 2009; 27: 519-50.
14. Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463: 540-4.
15. Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464: 1367-70.
16. Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Ac Sci USA 2009 2010; 107: 11489-94.
17. Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2001; 12: 1045-54.
18. Mjosberg JM, Trifari S, Crellin NK, et al. Human IL-25-and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2001; 12: 1055-62.
19. Bartemes KR, Iijima K, Kobayashi T, et al. IL-33-responsive lineage-CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188: 1503-13.
20. Halim TY, Krauss RH, Sun AC, et al. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergeninduced airway inflammation. Immunity 2012; 36: 451-63.
21. Oboki K, Ohno T, Kajiwara N, et al. IL-33 and IL-33 receptors in host defense and diseases. Allergol Ogy: off J Jap Soc Allergol 2010; 59: 143-60.
22. Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20: 791-800.
23. Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Ac Sci USA 2009 2010; 107: 18581-6.
24. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008; 3: e3331.
25. Pichery M, Mirey E, Mercier P, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012; 188: 3488-95.
26. Ohno T, Oboki K, Kajiwara N, et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009; 183: 7890-7.
27. Matsuyama Y, Okazaki H, Tamemoto H, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37: 18-25.
28. Andronicos NM, McNally J, Kotze AC, et al. Trichostrongylus colubriformis larvae induce necrosis and release of IL33 from intestinal epithelial cells in vitro: implications for gastrointestinal nematode vaccine design. Int J Parasitol 2012; 42: 295-304.
29. Le Goffic R, Arshad MI, Rauch M, et al. Infection with influenza virus induces IL-33 in murine lungs. Am J Respir Cell Mol Biol 2001; 45: 1125-32.
30. Andrei C, Margiocco P, Poggi A, et al. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Ac Sci USA 2009 2004; 101: 9745-50.
31. Qu Y, Franchi L, Nunez G, et al. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 2007; 179: 1913-25.
32. MacKenzie A, Wilson HL, Kiss-Toth E, et al. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2000; 15: 825-35.
33. Becker CE, Creagh EM, O'Neill LA. Rab39a binds caspase-1 and is required for caspase-1-dependent interleukin-1beta secretion. J Biol Chem 2009; 284: 34531-7.
34. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, et al. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Ac Sci USA 2009 2011; 108: 18055-60.
35. Keller M, Ruegg A, Werner S, et al. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132: 818-31.
36. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36: 388-400.
37. Lamkanfi M, Sarkar A, Vande Walle L, et al. Inflammasomedependent release of the alarminHMGB1in endotoxemia. J Immunol 2010; 185: 4385-92.
38. Dupont N, Jiang S, Pilli M, et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J 2011; 30: 4701-11.
39. Kouzaki H, Iijima K, Kobayashi T, et al. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011; 186: 4375-87.
40. Zhang L, Lu R, Zhao G, et al. TLR-mediated induction of pro-allergic cytokine IL-33 in ocular mucosal epithelium. Int J Biochem Cell Biol 2011; 43: 1383-91.
41. Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008; 84: 631-43.
42. Afonina IS, Tynan GA, Logue SE, et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Mol Cell 2011; 44: 265-78.
43. Lefrancais E, Roga S, Gautier V, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Ac Sci USA 2009 2012; 109: 1673-8.
44. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768-74.
45. Ghayur T, Banerjee S, Hugunin M, et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 1997; 386: 619-23.
46. Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Ann Rev Immunol 2001; 29: 707-35.
47. Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31: 84-98.
48. Talabot-Ayer D, Lamacchia C, Gabay C, et al. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009; 284: 19420-6.
49. Ali S, Nguyen DQ, Falk W, et al. Caspase 3 inactivates biologically active full length interleukin-33 as a classical cytokine but does not prohibit nuclear translocation. Biochem Biophys Res Commun 2010; 391: 1512-6.
50. Martin SJ, Henry CM, Cullen SP. A perspective on mammalian caspases as positive and negative regulators of inflammation. Mol Cell 2012; 46: 387-97.
51. Bae S, Kang T, Hong J, et al. Contradictory functions (activation/ termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity. J Biol Chem 2012; 287: 8205-13.
52. Monteseirin J, Neutrophils asthma. J Investig Allergol Clin Immunol 2009; 19: 340-54.
53. Cascao R, Rosario HS, Souto-CarneiroMM, Fonseca JE. Neutrophils in rheumatoid arthritis: More than simple final effectors. Autoimmun Rev 2010; 9: 531-5.
54. Fournier BM, Parkos CA. The role of neutrophils during intestinal inflammation. Mucosal Immunol 2012; 5: 354-66.
55. Fantuzzi G, Ku G, Harding MW, et al. Response to local inflammation of IL-1 beta-converting enzyme-deficient mice. J Immunol 1997; 158: 1818-24.
56. Tsutsui H, Kayagaki N, Kuida K, et al. Caspase-1-independent. Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999; 11: 359-67.
57. Hazuda DJ, Strickler J, Kueppers F, et al. Processing of precursor interleukin 1 beta and inflammatory disease. J Biol Chem 1990; 265: 6318-22.
58. Joosten LA, Netea MG, Fantuzzi G, et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum; 60: 3651-62.
59. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzymeindependent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Ac Sci USA 2009 1999; 96: 6261-6.
60. Mizutani H, Schechter N, Lazarus G, et al. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-5.
61. Guma M, Ronacher L, Liu-Bryan R, et al. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60: 3642-50.
62. Irmler M, Hertig S, MacDonald HR, et al. Granzyme A is an interleukin 1 beta-converting enzyme. J Exp Med 1995; 181: 1917-22.
63. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-60.
64. Sugawara S, Uehara A, Nochi T, et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J Immunol 2001; 167: 6568-75.
65. Omoto Y, Tokime K, Yamanaka K, et al. Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment. J Immunol 2006; 177: 8315-9.
66. Omoto Y, Yamanaka K, Tokime K, et al. Granzyme B is a novel interleukin-18 converting enzyme. J dermatol Sci 2010; 59: 129-35.
67. Howard AD, Kostura MJ, Thornberry N, et al. IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 beta precursor at two distinct sites and does not cleave 31-kDa IL-1 alpha. J Immunol 1991; 147: 2964-9.
68. Mosley B, Urdal DL, Prickett KS, et al. The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem 1987; 262: 2941-4.
69. Kobayashi Y, Yamamoto K, Saido T, et al. Identification of calciumactivated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Ac Sci USA 2009 1990; 87: 5548-52.
70. Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and-beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem 1995; 270: 27758-65.
71. Hayakawa M, Hayakawa H, Matsuyama Y, et al. Mature interleukin-33 is produced by calpain-mediated cleavage in vivo. Biochem Biophys Res Commun 2009; 387: 218-22.
72. Meephansan J, Tsuda H, Komine M, et al. Regulation of IL-33 Expression by IFN-gamma and Tumor Necrosis Factor-alpha in Normal Human Epidermal Keratinocytes. J Invest Dermatol 2012.
73. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011; 89: 383-92.
74. Kakkar R, Hei H, Dobner S, et al. Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 2012; 287: 6941-8.
75. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem 2011; 286: 42594-602.